Among the most successful fund investment fields, there are Health Care, Medical Device. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Supira Medical.
The common things for fund are deals in the range of 10 - 50 millions dollars. The fund is generally included in less than 2 deals every year. The important activity for fund was in 2018.
The typical case for the fund is to invest in rounds with 3 participants. The meaningful sponsors for the fund in investment in the same round are The Capital Partnership, Cormorant Asset Management.
Related Funds
| Fund Name | Location |
| 4G Ventures | Carmel, Indiana, United States |
| Altas Partners | - |
| Collaborative Ventures | Concord, North Carolina, United States |
| Endeit Capital | Amsterdam, Noord-Holland, The Netherlands |
| Mahaka Group Media | - |
| Samsung SDS | New Jersey, Ridgefield Park, United States |
| Shenzhen Dachaoshan Equity Investment Fund Co Ltd | China, Guangdong, Shenzhen |
| Spider Capital | California, San Francisco, United States |
| Yunyihua Tongxun | China, Shanghai |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Tioga Medical | $30M | 09 Feb 2023 | California, United States | ||
Adona Medical | $37M | 29 Apr 2022 | California, United States | ||
Akura Medical | $25M | 10 Jan 2022 | Campbell, California, United States | ||
Tioga Medical | $30M | 07 Jul 2021 | California, United States | ||
Supira Medical | $35M | 05 Mar 2020 | California, United States | ||
Supira Medical | $15M | 25 Apr 2018 | California, United States |
– Tioga Medical, Inc. announced the initial closing of its committed $30M Series B financing.
– Led by The Capital Partnership (TCP), with participation from Cormorant Asset Management, AMED Ventures and Shifamed angel investors.
– The financing will be used to advance product development, support pre-clinical testing, and initiate clinical experience for the company’s novel transcatheter valve replacement technology.
– Myra Vision, a maker of a glaucoma treatment device and Shifamed portfolio company, closed its $17M Series A financing.
– The round was led by The Capital Partnership (TCP) with participation from Cormorant Asset Management and Shifamed angel investors.
– The new investment will be used to advance product development, scale infrastructure, and expand the team in order to support the development of its glaucoma treatment device.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Tioga Medical | $30M | 09 Feb 2023 | California, United States | ||
Adona Medical | $37M | 29 Apr 2022 | California, United States | ||
Akura Medical | $25M | 10 Jan 2022 | Campbell, California, United States | ||
Tioga Medical | $30M | 07 Jul 2021 | California, United States | ||
Supira Medical | $35M | 05 Mar 2020 | California, United States | ||
Supira Medical | $15M | 25 Apr 2018 | California, United States |
